» Articles » PMID: 39746987

A Bayesian Active Learning Platform for Scalable Combination Drug Screens

Overview
Journal Nat Commun
Specialty Biology
Date 2025 Jan 2
PMID 39746987
Authors
Affiliations
Soon will be listed here.
Abstract

Large-scale combination drug screens are generally considered intractable due to the immense number of possible combinations. Existing approaches use ad hoc fixed experimental designs then train machine learning models to impute unobserved combinations. Here we propose BATCHIE, an orthogonal approach that conducts experiments dynamically in batches. BATCHIE uses information theory and probabilistic modeling to design each batch to be maximally informative based on the results of previous experiments. On retrospective experiments from previous large-scale screens, BATCHIE designs rapidly discover highly effective and synergistic combinations. In a prospective combination screen of a library of 206 drugs on a collection of pediatric cancer cell lines, the BATCHIE model accurately predicts unseen combinations and detects synergies after exploring only 4% of the 1.4M possible experiments. Further, the model identifies a panel of top combinations for Ewing sarcomas, which follow-up validation experiments confirm to be effective, including the rational and translatable top hit of PARP plus topoisomerase I inhibition. These results demonstrate that adaptive experiments can enable large-scale unbiased combination drug screens with a relatively small number of experiments. BATCHIE is open source and publicly available ( https://github.com/tansey-lab/batchie ).

Citing Articles

A Bayesian active learning platform for scalable combination drug screens.

Tosh C, Tec M, White J, Quinn J, Ibanez Sanchez G, Calder P Nat Commun. 2025; 16(1):156.

PMID: 39746987 PMC: 11696745. DOI: 10.1038/s41467-024-55287-7.

References
1.
Celik H, Sciandra M, Flashner B, Gelmez E, Kayraklioglu N, Allegakoen D . Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99. Oncogene. 2018; 37(16):2181-2196. PMC: 9936921. DOI: 10.1038/s41388-017-0080-4. View

2.
Engert F, Schneider C, WeiB L, Probst M, Fulda S . PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway. Mol Cancer Ther. 2015; 14(12):2818-30. DOI: 10.1158/1535-7163.MCT-15-0587. View

3.
Shoemaker R . The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006; 6(10):813-23. DOI: 10.1038/nrc1951. View

4.
Yang W, Soares J, Greninger P, Edelman E, Lightfoot H, Forbes S . Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2012; 41(Database issue):D955-61. PMC: 3531057. DOI: 10.1093/nar/gks1111. View

5.
Tosh C, Tec M, White J, Quinn J, Ibanez Sanchez G, Calder P . A Bayesian active learning platform for scalable combination drug screens. Nat Commun. 2025; 16(1):156. PMC: 11696745. DOI: 10.1038/s41467-024-55287-7. View